1d
Health on MSNWhat To Know About HR+/HER2- Breast CancerMedically reviewed by Marla Anderson, MD HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is ...
When breast cancer spreads to other parts of the body, it’s called metastatic breast cancer. Knowing the common places where ...
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...
A first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...
AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...
1d
GlobalData on MSNAstraZeneca reports positive outcomes from breast cancer combo therapy trialAstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...
The following is a summary of "HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials ...
Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results